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2017 University Grant Program, Seed Grant Final Report
Alyson J. Smith, Ph.D.
The purpose of this UGP proposal was to obtain preliminary data to elucidate the ability of different TLR
agonists, alone and in combination with one another and chemotherapy, to induce regression of solid tumors.
The specific objectives of this proposal were to: 1) evaluate the ability of a TLR7/8 and/or TLR4 agonist,
individually and in combination with one another and the chemotherapy cyclophosphamide, to induce growth
arrest or remission of tumors and 2) to dissect the underlying mechanism of action of these compounds on the
immune system and in the tumor microenvironment (TME). In support of these aims two in vivo studies of similar
structure were done (Figure 1).
In the initial study two
escalating doses of the TLR4
agonist CRX-527 and the
TLR7/8 agonist CRX-727 were
assessed alone and in
combination with one another
and/or the chemotherapy
cyclophosphamide (cytoxan).
Mice bearing CT-26 colon
Figure 1. Outline of solid tumor murine studies.
tumors on their flanks were
treated 3x 1/week. Toxicity in the combination groups after the first administration necessitated 2-fold decrease
in compound concentration upon reinjection (i.e. from 50/10 µg at week 1 to 25/5 µg at weeks 2 and 3). All
groups without the inclusion of the chemotherapy reached high tumor burden quickly, though addition of CRX527 did appear to slow the
growth of tumors (Figure 2,
upper). Cyclophosphamide on
its own was able to diminish
tumors but upon cessation of
treatment, tumors began to
rapidly regrow (Figure 2, lower
left, red line). Addition of higher
dose CRX-527 or the
combination of CRX-527/CRX727 to the chemo, induced
immunological memory
responses capable of
maintaining low tumor levels
(green, light red or yellow lines).
While CRX-527 synergized with
chemotherapy to decrease
tumor burden, the greatest
Figure 2. Colon tumor growth in response to treatment regimens.
effect on tumor decrease was
the addition of both TLR4 and TLR7/8 agonists (Figure 2, lower right, yellow and light red).
A follow up study was done with a lower dose of cytoxan and compounds to assess if greater synergy
would be seen at lower dose. Interestingly, decreasing the chemotherapy does by two-fold did not greatly
diminish the tumor ablation ability as was expected. With this lower chemotherapy dose though it was again
seen that tumor clearance by chemo was a transient phenotype that rebounded upon cessation of treatment
(Figure 3, lower left, red line). Interestingly, in this study the lower doses of the TLR4 agonist appear to be less
efficacious, while the TLR7/8 agonist (CRX-727) was actually more efficacious (Figure 3, lower right). With
either 5 or 1 µg CRX-527 there was no synergistic benefit to chemotherapy-induced tumor burden reduction or
induction of immunological memory (i.e. tumors again rebounded in size after treatment). However, with the
lowest dose of CRX-727 (1 µg) there was the greatest synergy and immunological memory when combined
with chemotherapy (Figure 3, lower figures). This interesting phenotype of increased activity of the TLR7/8
agonist alone at lower doses suggests a clear dose-dependent activity of all of these compounds. Whereby
titrating one or both is necessary to maximize response. In addition to assessing the TLR4 and TLR7/8
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compounds in this study a novel
compound was also included –
UM-1024, a purported Mincle
agonist. Mincle is a disparate
innate receptor thought to be
responsible for driving a Th17
response. While the role of
Th17 effort cells in cancer
therapy is not clearly elucidated
and often conflicting, we chose
to include this molecule to being
to elucidate this further.
Interestingly while the
compound on its own had no
effect at tumor reduction,
combination with the
chemotherapy was synergistic.
50% of the mice were cured of
the tumor when given this
Figure 3. Colon tumor growth in response to treatment regimens.
combination regimen (Figure 3,
lower right). Though not as efficacious as low dose TLR7/8 this compound presents an intruding path of study
and should be investigated more thoroughly.
In addition, in this study spleens were harvested from mice upon sacrifice (either because to tumor
burden or study end) and evaluated for immunophenotyping. Analysis of this data is complicated as different
groups were harvested/stained/analyzed at different times based on tumor burden and it appears there were
differences in staining across these groups making cross group comparison inaccurate. However, when the
median tumor volume of the end groups (those that made it to day 49 of the study, i.e. those with CTX) was
plotted against the percentage of several
different immune cell subtypes, some
correlations were garnered. Unexpectedly no
correlation between the percentage of M1
macrophages or Treg cells and tumor burden
were found (Figure 4A and E). Negative
correlation (i.e. more tumor was seen with less
cells) was seen for M MDSC, CD8 and CD4 T
cells (Figure 4D, F and G), while the increased
presence of M2 or PMN MDSC was positively
correlated (i.e. more tumor with more cells)
(Figure 4B and C). This data would suggest
that to drive successful tumor clearance
suppression the PMN myeloid derived
suppressor and the M2 macrophage subsets
must be diminished with augmentation of CD4
and CD8 T cell subsets.
Extramural Grant Submissions
In continuation of this work, and fulfilment of
UGP requirements, a U01 entitled ‘Investigation
of combinatorial innate immunotherapy with
chemotherapy to enhance responses in colon
cancer’ was submitted to the National Cancer
Institute in Jan of 2018 (application identifier
238684). Review is expected in late May 2018.

Figure 4. Correlation between final median tumor volume and
percent immune cell subtypes.
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